HC Wainwright Forecasts Nkarta’s Q3 Earnings (NASDAQ:NKTX)

Nkarta, Inc. (NASDAQ:NKTX) – Investment analysts at HC Wainwright issued their Q3 2026 earnings estimates for shares of Nkarta in a note issued to investors on Monday, November 2nd. HC Wainwright analyst D. Tsao forecasts that the company will earn ($0.46) per share for the quarter. HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Nkarta’s current full-year earnings is ($1.52) per share. HC Wainwright also issued estimates for Nkarta’s Q4 2026 earnings at ($0.48) EPS, FY2026 earnings at ($1.86) EPS, FY2027 earnings at ($2.26) EPS, FY2028 earnings at ($1.76) EPS, FY2029 earnings at ($1.57) EPS and FY2030 earnings at ($1.36) EPS.

A number of other research firms have also commented on NKTX. Stifel Nicolaus lowered their price target on Nkarta from $11.00 to $10.00 and set a “buy” rating for the company in a research report on Friday, August 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nkarta in a report on Monday, September 21st. Finally, Wall Street Zen lowered shares of Nkarta from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 15th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Nkarta currently has an average rating of “Moderate Buy” and a consensus target price of $11.20.

Nkarta Stock Up 0.7%

Shares of Nkarta stock opened at $1.53 on Wednesday. Nkarta has a 52 week low of $1.48 and a 52 week high of $3.72. The business has a 50 day moving average price of $2.40 and a 200-day moving average price of $2.52. The company has a market cap of $109.58 million, a PE ratio of -0.97 and a beta of 1.24.

Nkarta (NASDAQ:NKTX) last released its quarterly earnings results on Monday, August 10th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.18).

Hedge Funds Weigh In On Nkarta

Several institutional investors have recently bought and sold shares of NKTX. BlackRock Inc. bought a new position in Nkarta during the second quarter worth about $17,830,000. Monaco Asset Management SAM purchased a new position in Nkarta in the 2nd quarter worth approximately $6,717,000. AWM Investment Company Inc. purchased a new stake in Nkarta during the second quarter valued at about $2,564,000. Ieq Capital LLC purchased a new stake in Nkarta in the second quarter worth approximately $501,000. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of Nkarta by 74.4% in the 1st quarter. Dimensional Fund Advisors LP now owns 346,593 shares of the company’s stock worth $731,000 after acquiring an additional 147,894 shares during the last quarter. Hedge funds and other institutional investors own 80.54% of the company’s stock.

About Nkarta

Nkarta, Inc is a clinical-stage biotechnology company focused on developing engineered natural killer (NK) cell therapies for cancer and autoimmune diseases. The company’s platform is designed to produce allogeneic, or donor-derived, NK cells that can be engineered with chimeric antigen receptors (CARs) to recognize and attack targeted cells.

Nkarta’s research and development programs have included NKX019, a CD19-targeted CAR NK-cell therapy investigated for B-cell malignancies and autoimmune disorders, and NKX101, an NKG2D-targeted CAR NK-cell therapy developed for certain solid tumors.